Clinical Trials Logo

Filter by:
NCT ID: NCT04879732 Active, not recruiting - Hip Osteoarthritis Clinical Trials

RSA - ACTIS Hip Stem

Start date: October 5, 2021
Phase: N/A
Study type: Interventional

The principal objective of this study is to compare mean 2-year subsidence of the ACTIS femoral stem using model-based RSA against published migration patterns for hip stems of a similar design. Secondary objectives include comparison of migration per surgical approach, quantifying changes in functional and health status of subjects following surgery, and assess occurrences of complications and adverse events.

NCT ID: NCT04879628 Active, not recruiting - Multiple Sclerosis Clinical Trials

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

Start date: June 7, 2021
Phase: Phase 2
Study type: Interventional

Primary Objective: To determine the efficacy of SAR441344 as measured by reduction of the number of new active brain lesions Secondary Objective: - To evaluate efficacy of SAR441344 on disease activity as assessed by other MRI measures - To evaluate the safety and tolerability of SAR441344 - To evaluate pharmacokinetics of SAR441344

NCT ID: NCT04879329 Recruiting - Clinical trials for Urothelial Carcinoma

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Start date: May 3, 2022
Phase: Phase 2
Study type: Interventional

This study is being done to see if a drug called disitamab vedotin, alone or with pembrolizumab, works to treat HER2 expressing urothelial cancer. It will also test how safe the drug is for participants. Participants will have cancer that has spread in the body near where it started (locally advanced) and cannot be removed (unresectable) or has spread through the body (metastatic). It will also study what side effects happen when participants get the drug. A side effect is anything a drug does to your body besides treating the disease.

NCT ID: NCT04879134 Recruiting - Parkinson Disease Clinical Trials

Apomorphine Effects on Pain in Parkinson's Disease

Start date: February 28, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

To study the effects of acute apomorphine vs. placebo administration on different Parkinson's disease pain types.

NCT ID: NCT04878965 Completed - Technology Clinical Trials

Smartwatches to Manage Stress and Anxiety in Residential Settings

Smartwatch
Start date: April 26, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to conduct a prospective evaluation of a smartwatch technology and an associated application (developed by Awake Labs) in a clinical cohort from Centre for Addiction and Mental Health (CAMH) Adult Neurodevelopmental Services (ANS) and adults with developmental disabilities in the community who have received a watch.

NCT ID: NCT04878510 Active, not recruiting - Clinical trials for Respiratory Insufficiency

Non-invasive Ventilation and Dex in Critically Ill Adults

inDEX
Start date: March 7, 2022
Phase: Phase 3
Study type: Interventional

Non-Invasive ventilation (NIV) is a life saving intervention for patients with acute respiratory failure (ARF). Some patients are not able to tolerate the NIV intervention and ultimately fail, requiring the use of invasive mechanical ventilation (IMV) and intubation. Sedation may improve a patient's NIV tolerance. However, this practice has not been adopted by intensivists as the risk of over-sedation resulting in respiratory depression, inability to protect the airway, and inadvertent need for intubation are all large deterrents of sedative use in NIV. The Non-invasive Ventilation and Dexmedetomidine in Critically Ill Adults: a Vanguard Pragmatic Randomized Controlled Trial (inDEX) is looking to evaluate the effectiveness of dexmedetomidine compared to placebo in reducing non-invasive ventilation failures in patients admitted to the hospital with acute respiratory failure. The results from this pilot trial, will subsequently inform a large, pragmatic, powered trial to definitively address the question.

NCT ID: NCT04878354 Completed - Allergy Clinical Trials

A Study in Children and Adolescents With Birch Pollen-induced Rhinoconjunctivitis

TreeTop
Start date: April 7, 2021
Phase: Phase 3
Study type: Interventional

This is a clinical study in children and adolescents (5-17 years) with allergy to pollen from birch (or related trees). It compares the tree SLIT-tablet with placebo in relieving rhinoconjunctivitis symptoms during the birch/tree pollen season based on the average allergic rhinoconjunctivitis daily total combined score. The study will also collect health-related quality of life information in the groups treated with the tree SLIT-tablet or with placebo during the pollen season. The trial medication used is already approved to treat allergic rhinitis caused by birch/tree pollen in adults in several countries?.

NCT ID: NCT04877990 Completed - Ulcerative Colitis Clinical Trials

A Study to Evaluate the Long-term Safety and Efficacy of Deucravacitinib in Participants With Crohn's Disease or Ulcerative Colitis

Start date: May 7, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the long-term safety and efficacy of Deucravacitinib in participants who have previously been enrolled in a Deucravacitinib Phase 2 study for moderate to severe Crohn's disease or moderate to severe Ulcerative Colitis.

NCT ID: NCT04877899 Enrolling by invitation - Cancer Clinical Trials

Mazankowski Alberta Heart Institute (MAHI) EchoGo Discovery 1 Protocol

Start date: October 8, 2020
Phase:
Study type: Observational

This study aims to compare conventionally acquired Left Ventricle Ejection Fraction (LVEF) and Global Longitudinal Strain (GLS) data to Artificial Intelligence (AI) driven automated processing of 2 dimensional contrast and 2 dimensional non-contrast resting transthoracic echocardiograms for application in the assessment of patients undergoing chemotherapy with cardiotoxic drugs. This is a single-centre retrospective study which utilizes echocardiographic DICOM image and meta-data datasets received from a Canadian site. Data processed using the AI driven automated processing will be compared to conventionally acquired LVEF and GLS measurements and results will be analysed to determine accuracy and precision.

NCT ID: NCT04877522 Recruiting - Clinical trials for Chronic Myelogenous Leukemia

Asciminib Roll-over Study

Start date: August 30, 2022
Phase: Phase 4
Study type: Interventional

This is a long term safety study for patients who have completed a Novartis sponsored asciminib study and are judged by the investigator to benefit from continued treatment